PPA
ESPR

Parametric Portfolio Associates’s Esperion Therapeutics ESPR Stock Holding History

Parametric Portfolio Associates’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$791K Buy
170,404
+88,833
+109% +$381K ﹤0.01% 2890
2021
Q4 		$408K Sell
81,571
-4,247
-5% -$34K ﹤0.01% 3143
2021
Q3 		$1.03M Buy
85,818
+40,115
+88% +$584K ﹤0.01% 2798
2021
Q2 		$967K Sell
45,703
-11,640
-20% -$280K ﹤0.01% 2787
2021
Q1 		$1.61M Buy
57,343
+14,549
+34% +$429K ﹤0.01% 2922
2020
Q4 		$1.11M Sell
42,794
-848
-2% -$25.4K ﹤0.01% 2990
2020
Q3 		$1.62M Sell
43,642
-14,742
-25% -$584K ﹤0.01% 2639
2020
Q2 		$3M Buy
58,384
+10,271
+21% +$430K ﹤0.01% 2235
2020
Q1 		$1.52M Buy
48,113
+13,291
+38% +$701K ﹤0.01% 2551
2019
Q4 		$2.08M Buy
34,822
+7,336
+27% +$330K ﹤0.01% 2666
2019
Q3 		$1.01M Buy
27,486
+2,847
+12% +$113K ﹤0.01% 3026
2019
Q2 		$1.15M Buy
24,639
+1,903
+8% +$89.4K ﹤0.01% 2987
2019
Q1 		$913K Buy
22,736
+2,316
+11% +$104K ﹤0.01% 3077
2018
Q4 		$939K Buy
20,420
+279
+1% +$13.4K ﹤0.01% 3018
2018
Q3 		$894K Sell
20,141
-938
-4% -$43.1K ﹤0.01% 3159
2018
Q2 		$826K Sell
21,079
-24,614
-54% -$1.24M ﹤0.01% 3144
2018
Q1 		$3.31M Buy
45,693
+750
+2% +$55.1K ﹤0.01% 2238
2017
Q4 		$2.96M Sell
44,943
-4,392
-9% -$236K ﹤0.01% 2320
2017
Q3 		$2.47M Sell
49,335
-813
-2% -$39.2K ﹤0.01% 2440
2017
Q2 		$2.32M Buy
50,148
+1,386
+3% +$51K ﹤0.01% 2422
2017
Q1 		$1.72M Buy
48,762
+31,544
+183% +$722K ﹤0.01% 2551
2016
Q4 		$216K Sell
17,218
-3,949
-19% -$47K ﹤0.01% 3567
2016
Q3 		$293K Sell
21,167
-21,736
-51% -$246K ﹤0.01% 3428
2016
Q2 		$424K Buy
42,903
+32,566
+315% +$540K ﹤0.01% 3277
2016
Q1 		$175K Buy
+10,337
New +$166K ﹤0.01% 3771
2015
Q3 		– Sell
-5,203
Closed -$425K – 3286
2015
Q2 		$425K Buy
5,203
+775
+18% +$75.9K ﹤0.01% 3375
2015
Q1 		$410K Buy
+4,428
New +$286K ﹤0.01% 3382

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Parametric Portfolio Associates's ESPR Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Esperion Therapeutics (ESPR) stake by 109% in Q1 2022, buying an estimated $381K and bringing the position to 170,404 shares worth $791K. The position accounts for ﹤0.01% of the portfolio, ranked #2890.

Parametric Portfolio Associates first reported a position in ESPR in Q1 2015 and has held it in 27 quarters since. The position peaked at $3.31M in Q1 2018. 132 funds tracked by Wall St. Rank hold ESPR as of Q1 2022.

  • Parametric Portfolio Associates held 170,404 shares of Esperion Therapeutics worth $791K as of Q1 2022.
  • Parametric Portfolio Associates bought 88,833 Esperion Therapeutics shares in Q1 2022, an estimated $381K.
  • Esperion Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2890 holding.
  • Parametric Portfolio Associates first reported a position in Esperion Therapeutics in Q1 2015 and has held it in 27 quarters since.
  • Parametric Portfolio Associates's Esperion Therapeutics position peaked at $3.31M in Q1 2018.
  • 132 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.